Review



human p2y 14 receptor  (Keygen Biotech)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Keygen Biotech human p2y 14 receptor
    Mechanistic diagram of <t>P2Y</t> <t>14</t> R.
    Human P2y 14 Receptor, supplied by Keygen Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human p2y 14 receptor/product/Keygen Biotech
    Average 86 stars, based on 1 article reviews
    human p2y 14 receptor - by Bioz Stars, 2026-05
    86/100 stars

    Images

    1) Product Images from "Computational discovery and repurposing of chloramphenicol succinate as a potent P2Y 14 receptor antagonist for inflammatory bowel disease therapy"

    Article Title: Computational discovery and repurposing of chloramphenicol succinate as a potent P2Y 14 receptor antagonist for inflammatory bowel disease therapy

    Journal: Journal of Advanced Research

    doi: 10.1016/j.jare.2025.08.035

    Mechanistic diagram of P2Y 14 R.
    Figure Legend Snippet: Mechanistic diagram of P2Y 14 R.

    Techniques Used:

    Representative chemical structures of known P2Y 14 R antagonists.
    Figure Legend Snippet: Representative chemical structures of known P2Y 14 R antagonists.

    Techniques Used:

    Structural superposition of the five P2Y 14 R complexes.
    Figure Legend Snippet: Structural superposition of the five P2Y 14 R complexes.

    Techniques Used:

    Distribution of docking scores between known antagonists and decoy compounds using SP and XP scoring modes of Glide docking for five P2Y 14 R complexes.
    Figure Legend Snippet: Distribution of docking scores between known antagonists and decoy compounds using SP and XP scoring modes of Glide docking for five P2Y 14 R complexes.

    Techniques Used:

    Docking poses and chemical structures of (a) the top10 FDA approved drugs (b) the top10 FDA experimental drugs predicted as potential P2Y 14 R antagonists using DrugRep.
    Figure Legend Snippet: Docking poses and chemical structures of (a) the top10 FDA approved drugs (b) the top10 FDA experimental drugs predicted as potential P2Y 14 R antagonists using DrugRep.

    Techniques Used:

    Docking poses and chemical structures of (a) the top10 FDA approved drugs (b) the top10 FDA experimental drugs predicted as potential P2Y 14 R antagonists using Glide XP docking and MM/GBSA minimizations.
    Figure Legend Snippet: Docking poses and chemical structures of (a) the top10 FDA approved drugs (b) the top10 FDA experimental drugs predicted as potential P2Y 14 R antagonists using Glide XP docking and MM/GBSA minimizations.

    Techniques Used:

    The potential P2Y 14 R antagonists with the highest ranking from DrugBank, which include both approved and experimental drugs, were predicted using (a) AutoDock Vina of DrugRep and (b) Glide XP docking followed by MM/GBSA minimizations.
    Figure Legend Snippet: The potential P2Y 14 R antagonists with the highest ranking from DrugBank, which include both approved and experimental drugs, were predicted using (a) AutoDock Vina of DrugRep and (b) Glide XP docking followed by MM/GBSA minimizations.

    Techniques Used:

    (a) Per-residue interaction decomposition of the antagonist-P2Y 14 R binding free energy for P2Y 14 R· 7 and P2Y 14 R· DB07565 . (b) The 3D-cocrystal structure of P2Y 14 R with DB07565 . (c) Schematic representation of the GPCR-membrane complex.
    Figure Legend Snippet: (a) Per-residue interaction decomposition of the antagonist-P2Y 14 R binding free energy for P2Y 14 R· 7 and P2Y 14 R· DB07565 . (b) The 3D-cocrystal structure of P2Y 14 R with DB07565 . (c) Schematic representation of the GPCR-membrane complex.

    Techniques Used: Residue, Binding Assay, Membrane

    The DCCM analysis of apo and antagonistic P2Y 14 R system.
    Figure Legend Snippet: The DCCM analysis of apo and antagonistic P2Y 14 R system.

    Techniques Used:

    The free energy landscape analysis of apo-P2Y 14 R system and corresponding conformation in local energy minima.
    Figure Legend Snippet: The free energy landscape analysis of apo-P2Y 14 R system and corresponding conformation in local energy minima.

    Techniques Used:

    The free energy landscape analysis of (a) P2Y 14 R· 7 and (b) P2Y 14 R· DB07565 system and corresponding conformations in local energy minima.
    Figure Legend Snippet: The free energy landscape analysis of (a) P2Y 14 R· 7 and (b) P2Y 14 R· DB07565 system and corresponding conformations in local energy minima.

    Techniques Used:

    The in vitro biological testing of DB07565 . (a) In vitro P2Y 14 R antagonistic activity of DB07565 (N = 3). (b) The effect of DB07565 on cell viability of HT-29 cells (N = 5).
    Figure Legend Snippet: The in vitro biological testing of DB07565 . (a) In vitro P2Y 14 R antagonistic activity of DB07565 (N = 3). (b) The effect of DB07565 on cell viability of HT-29 cells (N = 5).

    Techniques Used: In Vitro, Activity Assay



    Similar Products

    human p2y 14 receptor  (Keygen Biotech)
    86
    Keygen Biotech human p2y 14 receptor
    Mechanistic diagram of <t>P2Y</t> <t>14</t> R.
    Human P2y 14 Receptor, supplied by Keygen Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human p2y 14 receptor/product/Keygen Biotech
    Average 86 stars, based on 1 article reviews
    human p2y 14 receptor - by Bioz Stars, 2026-05
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    Mechanistic diagram of P2Y 14 R.

    Journal: Journal of Advanced Research

    Article Title: Computational discovery and repurposing of chloramphenicol succinate as a potent P2Y 14 receptor antagonist for inflammatory bowel disease therapy

    doi: 10.1016/j.jare.2025.08.035

    Figure Lengend Snippet: Mechanistic diagram of P2Y 14 R.

    Article Snippet: Human embryonic kidney 293 (HEK293) cells, which stably express the human P2Y 14 receptor (hP2Y 14 -HEK293 cells), were obtained from Keygen Biotech Co., Ltd.

    Techniques:

    Representative chemical structures of known P2Y 14 R antagonists.

    Journal: Journal of Advanced Research

    Article Title: Computational discovery and repurposing of chloramphenicol succinate as a potent P2Y 14 receptor antagonist for inflammatory bowel disease therapy

    doi: 10.1016/j.jare.2025.08.035

    Figure Lengend Snippet: Representative chemical structures of known P2Y 14 R antagonists.

    Article Snippet: Human embryonic kidney 293 (HEK293) cells, which stably express the human P2Y 14 receptor (hP2Y 14 -HEK293 cells), were obtained from Keygen Biotech Co., Ltd.

    Techniques:

    Structural superposition of the five P2Y 14 R complexes.

    Journal: Journal of Advanced Research

    Article Title: Computational discovery and repurposing of chloramphenicol succinate as a potent P2Y 14 receptor antagonist for inflammatory bowel disease therapy

    doi: 10.1016/j.jare.2025.08.035

    Figure Lengend Snippet: Structural superposition of the five P2Y 14 R complexes.

    Article Snippet: Human embryonic kidney 293 (HEK293) cells, which stably express the human P2Y 14 receptor (hP2Y 14 -HEK293 cells), were obtained from Keygen Biotech Co., Ltd.

    Techniques:

    Distribution of docking scores between known antagonists and decoy compounds using SP and XP scoring modes of Glide docking for five P2Y 14 R complexes.

    Journal: Journal of Advanced Research

    Article Title: Computational discovery and repurposing of chloramphenicol succinate as a potent P2Y 14 receptor antagonist for inflammatory bowel disease therapy

    doi: 10.1016/j.jare.2025.08.035

    Figure Lengend Snippet: Distribution of docking scores between known antagonists and decoy compounds using SP and XP scoring modes of Glide docking for five P2Y 14 R complexes.

    Article Snippet: Human embryonic kidney 293 (HEK293) cells, which stably express the human P2Y 14 receptor (hP2Y 14 -HEK293 cells), were obtained from Keygen Biotech Co., Ltd.

    Techniques:

    Docking poses and chemical structures of (a) the top10 FDA approved drugs (b) the top10 FDA experimental drugs predicted as potential P2Y 14 R antagonists using DrugRep.

    Journal: Journal of Advanced Research

    Article Title: Computational discovery and repurposing of chloramphenicol succinate as a potent P2Y 14 receptor antagonist for inflammatory bowel disease therapy

    doi: 10.1016/j.jare.2025.08.035

    Figure Lengend Snippet: Docking poses and chemical structures of (a) the top10 FDA approved drugs (b) the top10 FDA experimental drugs predicted as potential P2Y 14 R antagonists using DrugRep.

    Article Snippet: Human embryonic kidney 293 (HEK293) cells, which stably express the human P2Y 14 receptor (hP2Y 14 -HEK293 cells), were obtained from Keygen Biotech Co., Ltd.

    Techniques:

    Docking poses and chemical structures of (a) the top10 FDA approved drugs (b) the top10 FDA experimental drugs predicted as potential P2Y 14 R antagonists using Glide XP docking and MM/GBSA minimizations.

    Journal: Journal of Advanced Research

    Article Title: Computational discovery and repurposing of chloramphenicol succinate as a potent P2Y 14 receptor antagonist for inflammatory bowel disease therapy

    doi: 10.1016/j.jare.2025.08.035

    Figure Lengend Snippet: Docking poses and chemical structures of (a) the top10 FDA approved drugs (b) the top10 FDA experimental drugs predicted as potential P2Y 14 R antagonists using Glide XP docking and MM/GBSA minimizations.

    Article Snippet: Human embryonic kidney 293 (HEK293) cells, which stably express the human P2Y 14 receptor (hP2Y 14 -HEK293 cells), were obtained from Keygen Biotech Co., Ltd.

    Techniques:

    The potential P2Y 14 R antagonists with the highest ranking from DrugBank, which include both approved and experimental drugs, were predicted using (a) AutoDock Vina of DrugRep and (b) Glide XP docking followed by MM/GBSA minimizations.

    Journal: Journal of Advanced Research

    Article Title: Computational discovery and repurposing of chloramphenicol succinate as a potent P2Y 14 receptor antagonist for inflammatory bowel disease therapy

    doi: 10.1016/j.jare.2025.08.035

    Figure Lengend Snippet: The potential P2Y 14 R antagonists with the highest ranking from DrugBank, which include both approved and experimental drugs, were predicted using (a) AutoDock Vina of DrugRep and (b) Glide XP docking followed by MM/GBSA minimizations.

    Article Snippet: Human embryonic kidney 293 (HEK293) cells, which stably express the human P2Y 14 receptor (hP2Y 14 -HEK293 cells), were obtained from Keygen Biotech Co., Ltd.

    Techniques:

    (a) Per-residue interaction decomposition of the antagonist-P2Y 14 R binding free energy for P2Y 14 R· 7 and P2Y 14 R· DB07565 . (b) The 3D-cocrystal structure of P2Y 14 R with DB07565 . (c) Schematic representation of the GPCR-membrane complex.

    Journal: Journal of Advanced Research

    Article Title: Computational discovery and repurposing of chloramphenicol succinate as a potent P2Y 14 receptor antagonist for inflammatory bowel disease therapy

    doi: 10.1016/j.jare.2025.08.035

    Figure Lengend Snippet: (a) Per-residue interaction decomposition of the antagonist-P2Y 14 R binding free energy for P2Y 14 R· 7 and P2Y 14 R· DB07565 . (b) The 3D-cocrystal structure of P2Y 14 R with DB07565 . (c) Schematic representation of the GPCR-membrane complex.

    Article Snippet: Human embryonic kidney 293 (HEK293) cells, which stably express the human P2Y 14 receptor (hP2Y 14 -HEK293 cells), were obtained from Keygen Biotech Co., Ltd.

    Techniques: Residue, Binding Assay, Membrane

    The DCCM analysis of apo and antagonistic P2Y 14 R system.

    Journal: Journal of Advanced Research

    Article Title: Computational discovery and repurposing of chloramphenicol succinate as a potent P2Y 14 receptor antagonist for inflammatory bowel disease therapy

    doi: 10.1016/j.jare.2025.08.035

    Figure Lengend Snippet: The DCCM analysis of apo and antagonistic P2Y 14 R system.

    Article Snippet: Human embryonic kidney 293 (HEK293) cells, which stably express the human P2Y 14 receptor (hP2Y 14 -HEK293 cells), were obtained from Keygen Biotech Co., Ltd.

    Techniques:

    The free energy landscape analysis of apo-P2Y 14 R system and corresponding conformation in local energy minima.

    Journal: Journal of Advanced Research

    Article Title: Computational discovery and repurposing of chloramphenicol succinate as a potent P2Y 14 receptor antagonist for inflammatory bowel disease therapy

    doi: 10.1016/j.jare.2025.08.035

    Figure Lengend Snippet: The free energy landscape analysis of apo-P2Y 14 R system and corresponding conformation in local energy minima.

    Article Snippet: Human embryonic kidney 293 (HEK293) cells, which stably express the human P2Y 14 receptor (hP2Y 14 -HEK293 cells), were obtained from Keygen Biotech Co., Ltd.

    Techniques:

    The free energy landscape analysis of (a) P2Y 14 R· 7 and (b) P2Y 14 R· DB07565 system and corresponding conformations in local energy minima.

    Journal: Journal of Advanced Research

    Article Title: Computational discovery and repurposing of chloramphenicol succinate as a potent P2Y 14 receptor antagonist for inflammatory bowel disease therapy

    doi: 10.1016/j.jare.2025.08.035

    Figure Lengend Snippet: The free energy landscape analysis of (a) P2Y 14 R· 7 and (b) P2Y 14 R· DB07565 system and corresponding conformations in local energy minima.

    Article Snippet: Human embryonic kidney 293 (HEK293) cells, which stably express the human P2Y 14 receptor (hP2Y 14 -HEK293 cells), were obtained from Keygen Biotech Co., Ltd.

    Techniques:

    The in vitro biological testing of DB07565 . (a) In vitro P2Y 14 R antagonistic activity of DB07565 (N = 3). (b) The effect of DB07565 on cell viability of HT-29 cells (N = 5).

    Journal: Journal of Advanced Research

    Article Title: Computational discovery and repurposing of chloramphenicol succinate as a potent P2Y 14 receptor antagonist for inflammatory bowel disease therapy

    doi: 10.1016/j.jare.2025.08.035

    Figure Lengend Snippet: The in vitro biological testing of DB07565 . (a) In vitro P2Y 14 R antagonistic activity of DB07565 (N = 3). (b) The effect of DB07565 on cell viability of HT-29 cells (N = 5).

    Article Snippet: Human embryonic kidney 293 (HEK293) cells, which stably express the human P2Y 14 receptor (hP2Y 14 -HEK293 cells), were obtained from Keygen Biotech Co., Ltd.

    Techniques: In Vitro, Activity Assay